The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a multi-biomarker approach.
Vermillion chief science officer and R&D VP Donald Munroe said: "We believe these tools represent the best diagnostic tools available today in the diagnosis and management of ovarian cancer, which is the leading cause of gynecologic cancer mortality."